Execution of Letter of Intent with Telexcell Trade PTE LTD, Singapore for Strategic Equity Investment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has executed a non-binding Letter of Intent with Singapore-based Telexcell Trade PTE LTD, which intends to acquire up to 25% equity stake in the company. The indicative price is ₹20 per share, representing a significant premium over the current market price of below ₹10. The transaction will be fully in cash and aims to strengthen Welcure's global footprint in pharmaceutical and chemical exports across emerging markets. The deal is subject to due diligence, execution of definitive agreements, and regulatory approvals from SEBI, RBI, and stock exchanges, with a 90-day window to complete these steps. The LOI is non-binding except for confidentiality and governing law provisions.
Positive for shareholders as the proposed investment price of ₹20 per share is more than double the prevailing market price, signaling strong valuation validation. However, the deal remains non-binding and conditional, so investors should wait for the definitive agreement and regulatory clearances before drawing firm conclusions.